Sarbajit Mukherjee: Trifluridine/ Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and GEJ Adenocarcinoma
Sarbajit Mukherjee, Chief of GI medical oncology at Miami Cancer Institute, posted on LinkedIn about recent paper he and his colleagues co-authored:
“Proud to announce that our clinical trial has been published!
This milestone represents six years of teamwork from its inception to its publication. It’s my first publication since joining Miami Cancer Institute. I’m grateful for the support from the National Comprehensive Cancer Network, Roswell Park Comprehensive Cancer Center colleagues, collaborators from the University of Oklahoma Health Sciences Center UChicago Medicine, and Natera.
This trial was especially personal as it was my first grant-funded study. Our team navigated challenging times during COVID-19 to achieve this.
A heartfelt thank you to the brave patients who participated in our study.”
Authors: Sarbajit Mukherjee, Hassan Hatoum et al.
More posts featuring Sarbajit Mukherjee.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023